Comparable stake leader
Nasrat A. Hakim
SEC ownership of ELITE PHARMACEUTICALS INC /NV/
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001053369.
Disclosed value leader
Nasrat A. Hakim
Comparable rows
0/10
Latest evidence
09 Oct 2026
- Public ticker
- ELTP on OTC
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Nasrat A. Hakim
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
09 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001053369
- Issuer location
- Northvale, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ELITE PHARMACEUTICALS INC /NV/ (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nasrat A. Hakim
Disclosed value leader
Nasrat A. Hakim
Comparable rows
0/10
Latest evidence
09 Oct 2026
3/4/5
13F
Highest disclosed value: $15,288,495
10 rows are not safely comparable across share classes.
Showing 1-8 of 10 holder rows.
Quick read
Nasrat A. Hakim has the largest disclosed position value at $15.29M.
0 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nasrat A. Hakim's linked filing trail.
Disclosed position value
Top 5
Nasrat A. Hakim
$15.29M
Douglas Plassche
$2.36M
Barry H. Dash
$874.4K
ELITE PHARMACEUTICALS INC /NV/
$129K
Jeffrey A. Whitnell
$116.3K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nasrat A. Hakim |
3/4/5
CEO, President, Director, 10%+ Owner
|
—
denominator unverified
|
$15,288,495
221,572,397 shares
|
— | 29 Mar 2024 |
| Douglas Plassche |
3/4/5
EVP Operations
|
—
mixed-class rows
|
$2,364,000
9,500,000 shares
mixed-class rows
|
— | 09 Jan 2026 |
| Barry H. Dash |
3/4/5
Director
|
—
denominator unverified
|
$874,371
3,365,555 shares
|
+$34,590 | 09 Oct 2026 |
| ELITE PHARMACEUTICALS INC /NV/ |
3/4/5
EVP Operations
|
—
mixed-class rows
|
$129,000
6,800,000 shares
mixed-class rows
|
— | 22 Aug 2025 |
| Jeffrey A. Whitnell |
3/4/5
Director
|
—
denominator unverified
|
$116,326
3,187,020 shares
|
— | 22 Nov 2023 |
| Davis S. Caskey |
3/4/5
Director
|
—
denominator unverified
|
$74,804
2,049,436 shares
|
— | 22 Nov 2023 |
| Kirko Kirkov |
3/4/5
Chief Commercial Officer
|
—
denominator unverified
|
$9,639
16,366 shares
|
— | 10 Jul 2025 |
| KELLEHER FINANCIAL ADVISORS |
13F
Company
|
—
denominator unverified
|
$365
1,000 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$34,590.
Buys
$34,590
Insiders: 1
Sells
$0
Insiders: 0
Net
+$34,590
Shares: +130,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 130,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 130,000 | 0 | $34,590 | $0 | +$34,590 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to ELITE PHARMACEUTICALS INC /NV/. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Nasrat A. Hakim
Net 12M change
+$34,590
Latest report
09 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Nasrat A. Hakim | CEO, President, Director, 10%+ Owner | $15,288,495 | Mixed | 29 Mar 2024 | ||
| Douglas Plassche | EVP Operations | $2,364,000 | Mixed | 09 Jan 2026 | ||
| Barry H. Dash | Director | $874,371 | +$34,590 | +4.1% | Filing P/S | 09 Oct 2026 |
| ELITE PHARMACEUTICALS INC /NV/ | EVP Operations | $129,000 | Mixed | 22 Aug 2025 | ||
| Jeffrey A. Whitnell | Director | $116,326 | Mixed | 22 Nov 2023 | ||
| Davis S. Caskey | Director | $74,804 | Mixed | 22 Nov 2023 | ||
| Kirko Kirkov | Chief Commercial Officer | $9,639 | Filing P/S | 10 Jul 2025 | ||
| Robert C. J. Chen | CFO, Secretary, Treasurer | Mixed | 16 May 2022 | |||
| Mark N. Pellegrino | CFO, Secretary, Treasurer | Mixed | 01 May 2023 | |||
| Marc Bregman | CFO, Secretary, Treasurer | Mixed | 17 May 2021 |
Recent insider transactions for ELITE PHARMACEUTICALS INC /NV/
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Barry H. Dash | ELTP | Common Stock | Purchase | 3.06% | $25,980 | $0.2598 | 100,000 | 3,365,555 | 09 Oct 2026 | Direct |
| Barry H. Dash | ELTP | Common Stock | Purchase | 0.93% | $8,610 | $0.2870 | 30,000 | 3,265,555 | 19 Aug 2026 | Direct |
| Douglas Plassche | ELTP | Stock Options (right to buy) | Options Exercise | 71.4% | 2,500,000 | 6,000,000 | 09 Jan 2026 | Direct | ||
| Douglas Plassche | ELTP | Stock Options (right to buy) | Options Exercise | -100% | -2,500,000 | 0 | 09 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.